Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as an essential therapy for type 2 diabetes mellitus (T2DM) due to their glycemic benefits and robust cardiovascular and renal protective effects. The gene discussed is SLC5A2; the disease is diabetes mellitus.